Please login to the form below

Not currently logged in
Email:
Password:

Bayer opens AI-enabled drug discovery center in UK

Seventh LifeHub opens in Reading’s Green Park

Bayer

Bayer has expanded its LifeHub network into the UK to apply artificial intelligence to drug discovery and disease diagnosis.

The German company has established LifeHubs at locations across Asia, Europe and the US. Each site has a different focus but shares a broad goal of connecting Bayer to the scientific community in that area.

Bayer has opened its seventh LifeHub in Reading’s Green Park, thereby bringing the network to the UK for the first time. The facility will focus on the application of AI to healthcare.

“We firmly believe that artificial intelligence has transformative potential for healthcare that can lead to enhancements in prediction, prevention and personalized treatments,” Kemal Malik, Bayer Board Member for Innovation, said in a statement.

That focus will see Bayer work to use AI in the optimisation of data-driven drug discovery. In the near term, Bayer will use the facility to support its existing relationship with clinical AI company Sensyne Health.

Sensyne began working with Bayer to apply AI to the discovery of new cardiovascular disease drugs earlier this year and will now become one of the first companies to move into LifeHub UK.

In conjunction with the opening of LifeHub UK, Bayer disclosed plans to expand its collaboration with Sensyne to cover the development of AI-enabled imaging technologies.

Bayer released the news about LifeHub UK on the same day as it disclosed details of the agreements it has entered into with 11 startups under its G4ADigital Health Partnerships programme.

The 11 companies are split into two groups. One set of companies will board the growth track, giving them a chance to receive €75,000 (£65,000) in funding and the opportunity to work at the headquarters of Bayer’s pharmaceuticals division in Berlin.

The second group of companies are more established. As part of Bayer’s advance track programme, these companies will work to co-create and execute commercial deals. Initial project funding and milestone payments are available to companies on the advance track.

Both tracks are supported by G4A, a programme that brings together all of Bayer’s digital health initiatives. Bayer has supported more than 150 digital health startups since establishing the programme in 2013.

Article by
Phil Taylor

14th October 2019

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics